|   |  UNITED STATES                      |   |
|--------|------------------------------------------|--------|
|   |  SECURITIES AND EXCHANGE COMMISSION |   |
|   |  WASHINGTON, DC 20549               |   |

|   |  NEVADA                          |   |   |  88-0390828         |   |
|--------|---------------------------------------|--------|--------|--------------------------|--------|
|   |  (State or other jurisdiction of |   |   |  I.R.S. Employer    |   |
|   |  incorporation or organization)  |   |   |  Identification No. |   |

|   |   |  Rontgenlaan 27, 2719 DX                              |   |   |
|--------|--------|------------------------------------------------------------|--------|--------|
|   |   |  Zoetermeer, The Netherlands                          |   |   |
|   |   |  (Address of principal executive offices)             |   |   |
|   |   |                                                       |   |   |
|   |   |  011-31-793-630-129                                   |   |   |
|   |   |  Registrant's telephone number, including area code   |   |   |
|   |   |                                                       |   |   |
|   |   |  N/A                                                  |   |   |
|   |   |  (Former name, former address and former fiscal year, |   |   |
|   |   |  if changed since last report)                        |   |   |
|   |   |                                                       |   |   |

|   |  Large accelerated filer o                                                              |   |   |  Accelerated filer  o   |   |
|--------|----------------------------------------------------------------------------------------------|--------|--------|-----------------------------------|--------|
|   |  Non-accelerated filer o   (Do not check if a smaller reporting company) |   |   |  Smaller reporting company x |   |
|   |                                                                                         |   |   |                              |   |

----

TABL

|  Item # |   |  Description                                                                     |   |  Page Numbers |
|--------------|--------|---------------------------------------------------------------------------------------|--------|--------------------|
|         |   |                                                                                  |   |               |   |
|         |   | PART I                                                                                |   |  4            |   |
|         |   |                                                                                  |   |               |   |
| ITEM 1       |   | FINANCIAL STATEMENTS                                                                  |   | 4                  |   |
|         |   |                                                                                  |   |               |   |
|  ITEM 2 |   | MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |   | 10                 |   |
|         |   |                                                                                  |   |               |   |
| ITEM 3       |   | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK                            |   | 11                 |   |
|         |   |                                                                                  |   |               |   |
| ITEM 4       |   | CONTROLS AND PROCEDURES                                                               |   | 12                 |   |
|         |   |                                                                                  |   |               |   |
|         |   | PART II                                                                               |   | 13                 |   |
|         |   |                                                                                  |   |               |   |
| ITEM 1       |   | LEGAL PROCEEDINGS                                                                     |   | 13                 |   |
|         |   |                                                                                  |   |               |   |
| ITEM 1A      |   | RISK FACTORS                                                                          |   | 13                 |   |
|         |   |                                                                                  |   |               |   |
| ITEM 2       |   | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS                           |   | 14                 |   |
|         |   |                                                                                  |   |               |   |
| ITEM 3       |   | DEFAULTS UPON SENIOR SECURITIES                                                       |   | 14                 |   |
|         |   |                                                                                  |   |               |   |
| ITEM 4       |   | [REMOVED AND RESERVED]                                                                |   | 14                 |   |
|         |   |                                                                                  |   |               |   |
| ITEM 5       |   | OTHER INFORMATION                                                                     |   | 14                 |   |
|         |   |                                                                                  |   |               |   |
| ITEM 6       |   | EXHIBITS                                                                              |   | 15                 |   |
|         |   |                                                                                  |   |               |   |
|         |   | SIGNATURES                                                                            |   | 16                 |   |
|         |   |                                                                                  |   |               |   |
| EXHIBIT 31.1 |   | SECTION 302 CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER                          |   |               |   |
|         |   |                                                                                  |   |               |   |
| EXHIBIT 31.2 |   | SECTION 302 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER                          |   |               |   |
|         |   |                                                                                  |   |               |   |
| EXHIBIT 32.1 |   | SECTION 906 CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER                          |   |               |   |
|         |   |                                                                                  |   |               |   |
| EXHIBIT 32.2 |   | SECTION 906 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER                          |   |               |   |

----

Table of Contents  

|   |    |                                                                                                                                                                                                   |
|--------|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   | • | risks arising from material weaknesses in our internal control over financial reporting, including material weaknesses in our control environment;                                                     |
|   |    |                                                                                                                                                                                                   |
|   | • | our ability to attract new clients and retain existing clients;                                                                                                                                        |
|   |    |                                                                                                                                                                                                   |
|   | • | our ability to retain and attract key employees;                                                                                                                                                       |
|   |    |                                                                                                                                                                                                   |
|   | • | risks associated with assumptions we make in connection with our critical accounting estimates;                                                                                                        |
|   |    |                                                                                                                                                                                                   |
|   | • | potential adverse effects if we are required to recognize impairment charges or other adverse accounting-related developments;                                                                         |
|   |    |                                                                                                                                                                                                   |
|   | • | potential downgrades in the credit ratings of our securities;                                                                                                                                          |
|   |    |                                                                                                                                                                                                   |
|   | • | risks associated with the effects of global, national and regional economic and political conditions, including fluctuations in economic growth rates, interest rates and currency exchange rates; and |
|   |    |                                                                                                                                                                                                   |
|   | • | developments from changes in the regulatory and legal environment for advertising and marketing and communications services companies around the world.                                                |

----

Table of Contents  

PART I

FINANCIAL STATEMENTS

|   |
|--------|

| Consolidated Balance Sheets as of June 30, 2012 and December 31, 2011(Unaudited) | Page      5 |
|---------------------------------------------------------------------------------------|-------------------------------------------|

| Consolidated Statements of Operations and Comprehensive Income for the three and six months ended June 30, 2012 and 2011 (unaudited) |   6 |
|------------------------------------------------------------------------------------------------------------------------------------------------|---------------|

| Consolidated Statements of Cash Flows for the six months ended June 30, 2012 and 2011 (unaudited) |   7 |
|---------------------------------------------------------------------------------------------------|----------|

| Notes to Consolidated Financial Statements (Unaudited) |   8 |
|--------------------------------------------------------|----------|

----

Table of Contents  

| GENMED HOLDING CORP. AND SUBSIDIARIES                                                                                                                                                  |     |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
|                                                                                                                                                                                   |     |   |   |   |   |   |
| CONSOLIDATED BALANCE SHEETS                                                                                                                                                            |     |
| (Unaudited)                                                                                                                                                                            |     |
|                                                                                                                                                                                   | June 30, |   |   | December 31, |   |
|                                                                                                                                                                                   | 2012     |   |   | 2011 |   |
|                                                                                                                                                                                   |     |   |   |   |   |   |
| ASSETS                                                                                                                                                                                 |     |   |   |   |   |   |
|                                                                                                                                                                                   |     |   |   |   |   |   |
| CURRENT ASSETS                                                                                                                                                                         |     |   |   |   |   |   |
| Cash                                                                                                                                                                                   |     | $ | 303,557 |   |   | $ | 904,489 |   |
| VAT receivable                                                                                                                                                                         |     |   | 3,985 |   |   |   | 8,082 |   |
| Deferred financing costs, Net                                                                                                                                                          |     |   | 63,034 |   |   |   | 90,906 |   |
| Prepaid Expenses                                                                                                                                                                       |     |   | 5,502 |   |   |   | 29,171 |   |
|     Total Current Assets                                                                                                                                           |     |   | 376,078 |   |   |   | 1,032,648 |   |
|                                                                                                                                                                                   |     |   |   |   |   |   |   |   |
| EQUIPMENT, net accumulated depreciation of $13,193 and $11,926 at June 30, 2012 and December 31, 2011, respectively                                                                    |     |   | 2,968 |   |   |   | 4,715 |   |
| Total Assets                                                                                                                                                                           |     | $ | 379,046 |   |   | $ | 1,037,363 |   |
|                                                                                                                                                                                   |     |   |   |   |   |   |   |   |
| LIABILITIES AND STOCKHOLDERS' EQUITY                                                                                                                                                   |     |   |   |   |   |   |   |   |
|                                                                                                                                                                                   |     |   |   |   |   |   |   |   |
| CURRENT LIABILITIES                                                                                                                                                                    |     |   |   |   |   |   |   |   |
| Accounts payable                                                                                                                                                                       |     |   | 98,895 |   |   |   | 89,297 |   |
| Accrued salaries                                                                                                                                                                       |     |   | 9,331 |   |   |   | 5,224 |   |
| Accrued expenses                                                                                                                                                                       |     |   | 44,667 |   |   |   | 7,770 |   |
| Accrued expenses - related parties                                                                                                                                                     |     |   | 3,472 |   |   |   | 3,575 |   |
| Loans payable to related parties                                                                                                                                                       |     |   | 37,728 |   |   |   | 38,850 |   |
|     Total Current Liabilities                                                                                                                                      |     |   | 194,093 |   |   |   | 144,716 |   |
|                                                                                                                                                                                   |     |   |   |   |   |   |   |   |
| LONG TERM LIABILITIES                                                                                                                                                                  |     |   |   |   |   |   |   |   |
|           Bonds payable, net of discount of $0 and $179,337 at June 30, 2012 and December 31, 2011, respectively                     |     |   | 2,542,202 |   |   |   | 2,508,865 |   |
|      Total Long Term Liabilities                                                                                                                              |     |   | 2,542,202 |   |   |   | 2,508,865 |   |
|                                                                                                                                                                                   |     |   |   |   |   |   |   |   |
| Total Liabilities                                                                                                                                                                      |     |   | 2,736,295 |   |   |   | 2,653,581 |   |
|                                                                                                                                                                                   |     |   |   |   |   |   |   |   |
| COMMITMENTS AND CONTINGENCIES                                                                                                                                                          |     |   | - |   |   |   | - |   |
|                                                                                                                                                                                   |     |   |   |   |   |   |   |   |
| STOCKHOLDERS' EQUITY                                                                                                                                                                   |     |   |   |   |   |   |   |   |
| Class A Convertible Preferred Stock, par value $0.001; authorized 500,000,000 shares; there were no shares issued and outstanding atJune 30, 2012 and December 31, 2011, respectively. |     |   | - |   |   |   | - |   |
| Common stock, par value $0.001; authorized 500,000,000 shares;issued and outstanding - 294,875,387 shares at June 30, 2012 and December 31, 2011, respectively.                        |     |   | 294,874 |   |   |   | 294,874 |   |
| Additional paid-in capital                                                                                                                                                             |     |   | 73,425,940 |   |   |   | 73,425,940 |   |
| Accumulated deficit                                                                                                                                                                    |     |   | (76,203,209 | ) |   |   | (75,437,616 | ) |
| Accumulated other comprehensive income (loss)                                                                                                                                          |     |   | 125,146 |   |   |   | 100,584 |   |
|     Total Stockholders' Equity                                                                                                                                     |     |   | (2,357,249 | ) |   |   | (1,616,218 | ) |
|                                                                                                                                                                                   |     |   |   |   |   |   |   |   |
|               Total Liabilities and Stockholders'  Equity                                                   |     | $ | 379,046 |   |   | $ | 1,037,363 |   |
|                                                                                                                                                                                   |     |   |   |   |   |   |   |   |
|                                                                                                                                                                                   |     |   |   |   |   |   |   |   |
|                                                                                                                                                                                   |     |   |   |   |   |   |   |   |
| See accompanying notes to unaudited consolidated financial statements                                                                                                                  |

----

Table of Contents  

| GENMED HOLDING CORP. AND SUBSIDIARIES                                 |   |
|-----------------------------------------------------------------------|--------|
|                                                                  |   |   |   |   |   |   |   |   |   |   |   |   |
| CONSOLIDATED STATEMENT OF OPERATIONS                                  |   |
| (Unaudited)                                                           |   |
|                                                                  |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                  |   | For the Three Months Ended |   |   | For the Six Months Ended |   |
|                                                                  |   | June 30, |   |   | June 30, |   |
|                                                                  |   | 2012 |   |   | 2011 |   |   | 2012 |   |   | 2011 |   |
|                                                                  |   |   |   |   |   |   |   |   |   |   |   |   |
| COST AND EXPENSES:                                                    |   |   |   |   |   |   |   |   |   |   |   |   |
| Selling, general and administrative                                   |   | $ | 322,487 |   |   | $ | 1,233,640 |   |   | $ | 594,984 |   |   | $ | 1,579,527 |   |
| Depreciation and amortization                                         |   |   | 823 |   |   |   | 922 |   |   |   | 1,663 |   |   |   | 1,788 |   |
| Research & development                                            |   |   | 20,344 |   |   |   | 21,455 |   |   |   | 53,194 |   |   |   | 47,690 |   |
|     Total Costs and Expenses                      |   |   | 343,654 |   |   |   | 1,256,017 |   |   |   | 649,841 |   |   |   | 1,629,005 |   |
|                                                                  |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| NET OPERATING LOSS                                                    |   |   | (343,654 | ) |   |   | (1,256,017 | ) |   |   | (649,841 | ) |   |   | (1,629,005 | ) |
|                                                                  |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| OTHER INCOME (EXPENSE)                                                |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Income (loss) on foreign exchange                                     |   |   | (3,829 | ) |   |   | 20,028 |   |   |   | 6,202 |   |   |   | 62,524 |   |
| Interest expense                                                      |   |   | (49,915 | ) |   |   | (64,411 | ) |   |   | (99,970 | ) |   |   | (121,680 | ) |
| Amortization - debt discount                                          |   |   | - |   |   |   | (141,434 | ) |   |   | - |   |   |   | (220,730 | ) |
| Amortization - deferred financing costs                               |   |   | (10,940 | ) |   |   | - |   |   |   | (21,984 | ) |   |   | - |   |
| Total Other Income (Expense)                                          |   |   | (64,684 | ) |   |   | (185,817 | ) |   |   | (115,752 | ) |   |   | (279,886 | ) |
|                                                                  |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| NET LOSS                                                              |   |   | (408,338 | ) |   |   | (1,441,834 | ) |   |   | (765,593 | ) |   |   | (1,908,891 | ) |
|                                                                  |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| COMPREHENSIVE INCOME, NET OF TAKS                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Other comprehensive income (loss)                                     |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Foreign currency translation adjustments                              |   |   | (78,567 | ) |   |   | (9,452 | ) |   |   | (125,146 | ) |   |   | 55,836 |   |
|                                                                  |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Comprehensive loss                                                    |   |   | (486,905 | ) |   |   | (1,451,286 | ) |   |   | (890,739 | ) |   |   | (1,853,055 | ) |
|                                                                  |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| NET LOSS PER COMMON SHARE                                             |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| (BASIC AND DILUTED)                                                   |   | $ | (0.00 | ) |   | $ | (0.01 | ) |   | $ | (0.00 | ) |   | $ | (0.01 | ) |
|                                                                  |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| WEIGHTED AVERAGE COMMON                                               |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| SHARES OUTSTANDING                                                    |   |   | 294,875,387 |   |   |   | 168,414,627 |   |   |   | 294,875,387 |   |   |   | 166,717,569 |   |
|                                                                  |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                  |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                                                  |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| See accompanying notes to unaudited consolidated financial statements |   |

----

Table of Contents  

| GENMED HOLDING CORP. AND SUBSIDIARIES                                                            |   |
|--------------------------------------------------------------------------------------------------|--------|
|                                                                                             |   |   |   |   |   |   |
| CONSOLIDATED STATEMENT OF CASH FLOWS                                                             |   |
|   (Unaudited)                                                                               |   |
|                                                                                             |   |   |   |   |   |   |
|                                                                                             |   | For the six months ended |   |
|                                                                                             |   | June 30, |   |
|                                                                                             |   | 2012 |   |   | 2011 |   |
| CASH FLOWS FROM OPERATING ACTIVITIES                                                             |   |   |   |   |   |   |
| Net loss                                                                                         |   | $ | (765,593 | ) |   | $ | (1,908,891 | ) |
| Adjustments to reconcile net loss to cash flows used in operating activities:                    |   |   |   |   |   |   |   |   |
| Depreciation and amortization                                                                    |   |   | 1,663 |   |   |   | 1,788 |   |
| Amortization of beneficial conversion feature                                                    |   |   | - |   |   |   | 220,730 |   |
| Amortization of deferred financing costs                                                         |   |   | 21,984 |   |   |   | - |   |
| Stock-based compensation                                                                         |   |   | - |   |   |   | 870,040 |   |
| Changes in operating assets and liabilities:                                                     |   |   |   |   |   |   |   |   |
| VAT receivable                                                                                   |   |   | 4,097 |   |   |   | 26,793 |   |
|  Amount due from related party                                                              |   |   | - |   |   |   | 315,630 |   |
| Prepaid expenses                                                                                 |   |   | 23,669 |   |   |   | 14,028 |   |
| Accounts payable                                                                                 |   |   | 9,598 |   |   |   | (63,747 | ) |
| Accrued salaries                                                                                 |   |   | 4,107 |   |   |   | (33,617 | ) |
| Accrued expenses                                                                                 |   |   | 36,897 |   |   |   | 31,803 |   |
| Accrued expenses - related parties                                                               |   |   | (103 | )  |   |   | 47,091 |   |
|     Net Cash Used in Operating Activities                                    |   |   | (663,681 | ) |   |   | (478,352 | ) |
|                                                                                             |   |   |   |   |   |   |   |   |
| CASH FLOWS FROM INVESTING ACTIVITIES                                                             |   |   |   |   |   |   |   |   |
|           NetCash Used in Investing Activities |   |   | - |   |   |   | - |   |
|                                                                                             |   |   |   |   |   |   |   |   |
| CASH FLOWS FROM FINANCING ACTIVITIES                                                             |   |   |   |   |   |   |   |   |
| Borrowings on bonds                                                                         |   |   | 62,880 |   |   |   | 1,318,124 |   |
| Payments of financing fees                                                                       |   |   | (2,232 | ) |   |   | - |   |
| Payments on loans payable to related parties                                                     |   |   | - |   |   |   | (78,322 | ) |
|         Net Cash Provided by Investing Activities        |   |   | 60,648 |   |   |   | 1,239,802 |   |
|                                                                                             |   |   |   |   |   |   |   |   |
| EFFECT OF CHANGE IN EXCHANGE RATE                                                                |   |   | 2,101 |   |   |   | (51,699 | ) |
|                                                                                             |   |   |   |   |   |   |   |   |
| INCREASE (DECREASE) IN CASH                                                                      |   |   | (600,932 | ) |   |   | 709,751 |   |
|                                                                                             |   |   |   |   |   |   |   |   |
| CASH, BEGINNING OF PERIOD                                                                        |   |   | 904,489 |   |   |   | 868,770 |   |
| CASH, END OF PERIOD                                                                              |   | $ | 303,557 |   |   | $ | 1,578,521 |   |
|                                                                                             |   |   |   |   |   |   |   |   |
| SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION                                                |   |   |   |   |   |   |   |   |
|                                                                                             |   |   |   |   |   |   |   |   |
| CASH PAID FOR:                                                                                   |   |   |   |   |   |   |   |   |
| Interest                                                                                         |   | $ | 100,073 |   |   | $ | 98,759 |   |
| Taxes                                                                                            |   | $ | - |   |   | $ | - |   |
|                                                                                             |   |   |   |   |   |   |   |   |
| NON-CASH INVESTING AND FINANCING TRANSACTIONS:                                                   |   |   |   |   |   |   |   |   |
| Conversion of convertible debentures into common stock                                           |   | $ | - |   |   | $ | 1,146,557 |   |
| Conversion of subordinated convertible debentures into common stock                              |   | $ | - |   |   | $ | 70,757 |   |
|  Conversion of accrued interest into common stock                                           |   | $ | - |   |   | $ | 38,000 |   |
|  Conversion of accrued expenses and loans to subordinated notes                             |   | $ | - |   |   | $ | - |   |
| Issuance of common stock for promotional services                                                |   | $ | - |   |   | $ | 20,040 |   |
|  Issuance of common stock for consultancy services                                          |   | $ | - |   |   | $ | 850,000 |   |
| Beneficial conversion feature on bonds payable charged to additional paid-in capital             |   | $ | - |   |   | $ | 256,594 |   |
|                                                                                             |   |   |   |   |   |   |   |   |
|                                                                                             |   |   |   |   |   |   |   |   |
| See accompanying notes to unaudited consolidated  financial statements                 |

----

Table of Contents  

NOTES

----

Table of Contents  

| Year Ending         |   | Amount |      |
|---------------------|--------|--------|-----------|
|  June 30, 2013 |   | $      | -         |   |
| June 30, 2014       |   |   | -         |   |
|  June 30, 2015 |   |   | 2,277,426 |   |
|  June 30, 2016 |   |   | 240,201   |   |
|  Total         |   | $      | 2,517,627 |   |

----

Table of Contents  

Management'

----

Table of Contents  

----

Table of Contents  

Item 3.  Quantitative 

Item 4.  Controls 

----

Table of Contents  

| ·   | As of June 30, 2012, there was a lack of accounting personnel with the requisite knowledge of Generally Accepted Accounting Principles (“GAAP”) in the US and the financial reporting requirements of the Securities and Exchange Commission. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | As of June 30, 2012, there were insufficient written policies and procedures to insure the correct application of accounting and financial reporting with respect to current requirements of GAAP and SEC disclosure requirements. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | As of June 30, 2012, there was a lack of segregation of duties, in that we had only one person performing all accounting-related duties. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | As of June 30, 2012, there were no independent directors and no independent audit committee. |
|--------------------|----------------------------------------------------------------------------------------------|

PART II 

Item 1.  

Item 1A.

----

Table of Contents  

Item 2.  Unregistered 

----

Table of Contents  

Item 3.  Defaults 

Item 4.  [Removed 

Item 5.  Other 

Exhibi

| Exhibit    10.1 | Stock Exchange Agreement between the Company and Joost de Metz (“de Metz”), Willem Blijleven (“Blijleven”), Erwin R. Bouwens (“Bouwens”) and Medical Network Holding BV dated April 17, 2008, incorporated herein by reference to Exhibit 9.2 to the Form 8-K current  report of the Company filed on May 2, 2008. |
|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Exhibit    10.2 | General Release and Settlement Agreement, incorporated herein by reference to Exhibit 9.1 to the Form 8-K current report of the Company filed on May 2, 2008. |
|-------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Exhibit    10.3 | Consulting Agreement between the Company and London Finance Group, Ltd., | incorporated herein by reference to Exhibit 9.1 to the Form 8-K current report of the Company filed on May 2, 2008. |
|-------------------------------------|-------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|

| Exhibit    10.4 | Release and Settlement Agreement between the Company, Joost de Metz, Willem Blijleven,  E.R. Bouwens Beheermaatschappij B.V., Medical Network Holding BV, Total Look, BV, London Finance Group, Ltd.,  Dojo Enterprises, LLC,  Hyperion Fund, L.P.,  The Palisades Capital, LLC 401(k) Profit Sharing Trust, The Morpheus 2005 Trust dated December 1, 2005, Burton Partners, LLC, Picasso, LLC  and Glacier, LLC, incorporated herein by reference to Exhibit 10.2 to the Form 10-K annual report of the Company filed on May 15, 2009. |
|-------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Exhibit    31.1 | Certification of the Principal Executive Officer Pursuant to Rule 13A-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Exhibit    31.2 | Certification of the Principal Financial Officer Pursuant to Rule 13A-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Exhibit    32.1 | Certification of the Principal Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|-------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|

| Exhibit    32.2 | Certification of the Principal Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|-------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|

----

SIG

| Dated:  August 14, 2012 | Genmed Holding Corp.                 |
|-----------------------------------|--------------------------------------|
|                              |                                 |
|                              |                                 |
|                              | By: /s/ Randy Hibma                  |
|                              | Randy Hibma, Chief Financial Officer |

----